Clinical Trial Update: A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH) [Phase 3]

View source ↗

Summary

Phase 3 trial investigating fremanezumab for prevention of chronic cluster headache was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cluster Headache

Drugs mentioned

• Fremanezumab (fremanezumab)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Chronic Cluster Headache | Phase 3 | Status: TERMINATED | Results posted: 2019-09-18